Chicago Equity Partners LLC boosted its position in Chemours Company (The) (NYSE:CC) by 58.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 426,899 shares of the specialty chemicals company’s stock after buying an additional 156,745 shares during the period. Chemours Company (The) makes up approximately 0.7% of Chicago Equity Partners LLC’s portfolio, making the stock its 18th biggest position. Chicago Equity Partners LLC owned approximately 0.23% of Chemours Company (The) worth $21,605,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Financial Architects Inc raised its holdings in shares of Chemours Company (The) by 1,230.3% in the 2nd quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock worth $111,000 after purchasing an additional 2,719 shares during the period. Acrospire Investment Management LLC raised its holdings in shares of Chemours Company (The) by 3.4% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,076 shares of the specialty chemicals company’s stock worth $117,000 after purchasing an additional 100 shares during the period. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Chemours Company (The) by 2,138.8% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock worth $118,000 after purchasing an additional 2,973 shares during the period. Smithfield Trust Co. raised its holdings in Chemours Company (The) by 521.4% during the 2nd quarter. Smithfield Trust Co. now owns 4,791 shares of the specialty chemicals company’s stock valued at $182,000 after acquiring an additional 4,020 shares during the period. Finally, Alps Advisors Inc. bought a new stake in Chemours Company (The) during the 2nd quarter valued at $202,000. Institutional investors and hedge funds own 73.23% of the company’s stock.

Chemours Company (CC) traded up $1.30 during trading hours on Monday, hitting $53.46. 789,305 shares of the stock were exchanged, compared to its average volume of 1,994,542. Chemours Company has a 1 year low of $16.39 and a 1 year high of $58.08. The company has a current ratio of 2.19, a quick ratio of 1.63 and a debt-to-equity ratio of 5.07. The stock has a market capitalization of $9,658.11, a PE ratio of 18.50, a price-to-earnings-growth ratio of 0.93 and a beta of 3.59.

Chemours Company (The) (NYSE:CC) last issued its earnings results on Thursday, November 2nd. The specialty chemicals company reported $1.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.01 by $0.11. Chemours Company (The) had a net margin of 4.86% and a return on equity of 116.80%. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.59 billion. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the company posted $0.61 earnings per share. sell-side analysts forecast that Chemours Company will post 3.63 EPS for the current year.

A number of brokerages have issued reports on CC. Zacks Investment Research cut shares of Chemours Company (The) from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 18th. UBS AG upped their target price on shares of Chemours Company (The) from $50.00 to $59.00 and gave the stock a “neutral” rating in a research report on Friday. Jefferies Group LLC upped their target price on shares of Chemours Company (The) to $60.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. BidaskClub upgraded shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. Finally, J P Morgan Chase & Co upped their price target on shares of Chemours Company (The) to $55.00 and gave the company an “overweight” rating in a research report on Friday, August 4th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $53.88.

In other Chemours Company (The) news, insider E Bryan Snell sold 10,000 shares of Chemours Company (The) stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.24, for a total value of $462,400.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Amy Trojanowski sold 2,500 shares of Chemours Company (The) stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.03, for a total transaction of $115,075.00. The disclosure for this sale can be found here. Insiders have sold a total of 77,142 shares of company stock worth $3,953,265 over the last 90 days. Insiders own 1.14% of the company’s stock.

WARNING: “Chemours Company (The) (CC) Shares Bought by Chicago Equity Partners LLC” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/chemours-company-the-cc-shares-bought-by-chicago-equity-partners-llc/1682837.html.

Chemours Company (The) Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.